Finance

Lists
7733:TYO
Olympus Corp
JP¥1 776,00
-0,81%
(-14,50) 1D
13 Nov., 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 7733...
Open
JP¥1 784
High
JP¥1 795
Low
JP¥1 754
Mkt. cap
1,98 bn
Avg. vol.
5,41 m
Volume
3,30 m
Dividend
1,69%
Quarterly dividend
JPÂ¥8
Ex-dividend date
30 Mrt. 2027
P/E ratio
21,12
52-wk high
JP¥2 210
52-wk low
JP¥1 302
EPS
JPÂ¥84
Shares outstanding
341,42 m
No. of employees
28 k
Open
JP¥1 784
High
JP¥1 795
Low
JP¥1 754
Mkt. cap
1,98 bn
Avg. vol.
5,41 m
Volume
3,30 m
Dividend
1,69%
Quarterly dividend
JPÂ¥8
Ex-dividend date
30 Mrt. 2027
P/E ratio
21,12
52-wk high
JP¥2 210
52-wk low
JP¥1 302
EPS
JPÂ¥84
Shares outstanding
341,42 m
No. of employees
28 k
News stories
From web sources and news partners
Profile
Olympus Corporation is a Japanese manufacturer of optics and reprography products, headquartered in Hachioji, Tokyo. Olympus was founded on October 12, 1919 as Takachiho Seisakusho by Takeshi Yamashita, initially specializing in microscopes and thermometers, and later in imaging. In 1921, the name Olympus was registered as a trademark. In 1942, the company was renamed Takachiho Optical Industries, and in 1949 it was renamed Olympus Optical Co., Ltd. In 2003, the company adopted its current name, Olympus Corporation. Olympus holds roughly a 70 percent share of the global endoscope market, estimated to be worth approximately US$2.5 billion. As of 2025, endoscopes and related surgical technologies are now Olympus's exclusive product line. It was formerly also a maker of cameras, camera lenses and dictaphones, until it divested this part to OM Digital Solutions in 2020. It divested from its microscopy and scientific imaging division in 2023, selling it to Bain Capital for approximately $3.1 billion; the division operates as Evident Corporation. Wikipedia
About Olympus Corp
CEOYasuo Takeuchi
Employees28,1 k
Founded12 Okt. 1919
Headquarters-
SectorHealth Care
IndustryMedical device
Last report
10 Nov. 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
269,19 mjd / 267,53 mjd
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
261,04 mjd
295,28 mjd
254,80 mjd
269,19 mjd
Cost of goods sold
96,15 mjd
102,52 mjd
80,82 mjd
78,06 mjd
Cost of revenue
96,15 mjd
102,52 mjd
80,82 mjd
78,06 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
125,65 mjd
104,14 mjd
125,56 mjd
126,10 mjd
Operating expense
140,86 mjd
133,39 mjd
128,74 mjd
135,24 mjd
Total operating expenses
237,01 mjd
235,91 mjd
209,56 mjd
213,30 mjd
Operating income
24,04 mjd
59,37 mjd
45,24 mjd
55,89 mjd
Other non operating income
-
-866,00 m
482,00 m
-
EBT including unusual items
22,13 mjd
27,08 mjd
41,30 mjd
55,04 mjd
EBT excluding unusual items
22,13 mjd
59,58 mjd
43,56 mjd
55,04 mjd
Income tax expense
7,96 mjd
2,26 mjd
15,23 mjd
22,00 mjd
Effective tax rate
35,98%
8,36%
36,87%
39,97%
Other operating expenses
15,21 mjd
-5,95 mjd
3,18 mjd
9,15 mjd
Net income
14,17 mjd
24,82 mjd
26,07 mjd
33,04 mjd
Net profit margin
5,43%
8,40%
10,23%
12,28%
Earnings per share
-
-
-
-
Interest and investment income
356,00 m
3,96 mjd
958,50 m
1,45 mjd
Interest expense
-2,34 mjd
-2,88 mjd
-2,62 mjd
-2,41 mjd
Net interest expenses
-1,99 mjd
1,09 mjd
-1,66 mjd
-966,00 m
Depreciation and amortization charges
-
35,20 mjd
-
-
EBITDA
41,76 mjd
75,92 mjd
62,97 mjd
74,04 mjd
Gain or loss from assets sale
-
12,08 mjd
-
-
Upcoming events
AI content may include mistakes. Learn more
Google-programme